1
|
Kim JA, Lee JK, Lee SY. Serum trace elements during treatment in pancreatic cancer patients and their associations with cancer prognosis. Clin Nutr 2024; 43:1459-1472. [PMID: 38714150 DOI: 10.1016/j.clnu.2024.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 02/27/2024] [Accepted: 04/09/2024] [Indexed: 05/09/2024]
Abstract
BACKGROUND & AIMS In this study, we assessed serum trace element concentrations in patients with pancreatic cancer and compared the results to those of healthy controls and patients with chronic pancreatitis. We evaluated the association between trace element concentrations during cancer treatment and the risk of cancer progression and mortality in pancreatic cancer patients. METHODS A retrospective cohort study was conducted at a tertiary center in Korea. Serum trace element concentrations of cobalt (Co), copper (Cu), selenium (Se), and zinc (Zn) were measured at diagnosis using an inductively coupled plasma-mass spectrometry in 124 patients with pancreatic cancer, 50 patients with chronic pancreatitis, and 120 healthy controls. Trace elements were measured after a median of 282.5 (95% confidence interval [CI], 224.0-326.5) days from treatment initiation to assess changes in trace element concentrations during treatment. RESULTS Serum Co concentrations were significantly higher in patients with chronic pancreatitis and pancreatic cancer compared to healthy controls, while serum Se concentrations were significantly lower. During treatment, serum concentrations of Cu, Se, and Zn significantly decreased in patients with pancreatic cancer. During the follow-up (median 152.5; 95% CI, 142.8-160.0 months), 85.5% of patients experienced progression or relapse, and 84.7% of patients died. Patients with decreased Se and Zn concentrations during treatment had a higher mortality (hazard ratio [HR], 2.10; 95% CI, 1.31-3.38; P = 0.0020 for Se; HR, 1.72; 95% CI, 1.06-2.79; P = 0.0269 for Zn) compared to those with unchanged or increased trace element concentrations during treatment. Patients with a greater reduction in Zn concentrations during treatment had a higher mortality than those with a smaller reduction (HR, 1.59; 95% CI, 1.01-2.52; P = 0.0483). Patients whose Zn status changed from normal to deficient during treatment had an increased mortality (HR, 1.76; 95% CI, 1.16-2.67, P = 0.0084). Patients with multiple (≥2) trace element deficiencies after treatment had poorer outcomes than those with no or single trace element deficiency. CONCLUSIONS This study revealed that decreases in Se and Zn concentrations during cancer treatment were associated with adverse outcomes in terms of cancer progression and mortality in patients with pancreatic cancer. Further prospective investigations are recommended.
Collapse
Affiliation(s)
- Jee Ah Kim
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea; Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, South Korea
| | - Jong Kyun Lee
- Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.
| | - Soo-Youn Lee
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.
| |
Collapse
|
2
|
Chen W, Hao P, Song Q, Feng X, Zhao X, Wu J, Gong Z, Zhang J, Fu X, Wang X. Methylseleninic acid inhibits human glioma growth in vitro and in vivo by triggering ROS-dependent oxidative damage and apoptosis. Metab Brain Dis 2024; 39:625-633. [PMID: 38416338 DOI: 10.1007/s11011-024-01344-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 02/25/2024] [Indexed: 02/29/2024]
Abstract
Selenium-containing agents showed novel anticancer activity by triggering pro-oxidative mechanism. Studies confirmed that methylseleninic acid (MeSe) displayed broad-spectrum anti-tumor activity against kinds of human cancers. However, the anticancer effects and mechanism of MeSe against human glioma growth have not been explored yet. Herein, the present study showed that MeSeA dose-dependently inhibited U251 and U87 human glioma cells growth in vitro. Flow cytometry analysis indicated that MeSe induced significant U251 cells apoptosis with a dose-dependent manner, followed by the activation of caspase-7, caspase-9 and caspase-3. Immunofluorescence staining revealed that MeSe time-dependently caused reactive oxide species (ROS) accumulation and subsequently resulted in oxidative damage, as convinced by the increased phosphorylation level of Ser428-ATR, Ser1981-ATM, Ser15-p53 and Ser139-histone. ROS inhibition by glutathione (GSH) effectively attenuated MeSe-induced ROS generation, oxidative damage, caspase-3 activation and cytotoxicity, indicating that ROS was an upstream factor involved in MeSe-mediated anticancer mechanism in glioma. Importantly, MeSe administration in nude mice significantly inhibited glioma growth in vivo by inducing apoptosis through triggering oxidative damage. Taken together, our findings validated the possibility that MeSe as a selenium-containing can act as potential tumor chemotherapy agent for therapy of human glioma.
Collapse
Affiliation(s)
- Wang Chen
- Department of Neurology, People's Hospital of Linyi, Linyi, 276000, Shandong, China
| | - Pida Hao
- Department of Neurology, Linyi Third People's Hospital, Linyi, 276023, Shandong, China
| | - Qile Song
- Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, Shandong, China
| | - Xiaotong Feng
- Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, Shandong, China
| | - Xuan Zhao
- Department of Neurology, People's Hospital of Linyi, Linyi, 276000, Shandong, China
| | - Jincheng Wu
- Department of Neurology, People's Hospital of Linyi, Linyi, 276000, Shandong, China
| | - Zixiang Gong
- Department of Neurology, People's Hospital of Linyi, Linyi, 276000, Shandong, China
| | - Jinli Zhang
- Department of Neurology, Feixian People's Hospital, Linyi, 273400, Shandong, China.
| | - Xiaoyan Fu
- Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, Shandong, China.
- Shandong Key Laboratory of TCM Multi-Target Intervention and Disease Control, The Second Affiliated Hospital of Shandong First Medical University Taian, Taian, 271000, Shandong, China.
| | - Xianjun Wang
- Department of Neurology, People's Hospital of Linyi, Linyi, 276000, Shandong, China.
| |
Collapse
|
3
|
Behera C, Kaur Sandha K, Banjare N, Kumar Shukla M, Mudassir Ali S, Singh M, Gupta PN. Biodegradable nanocarrier of gemcitabine and tocopherol succinate synergistically ameliorates anti-proliferative response in MIA PaCa-2 cells. Int J Pharm 2024; 649:123599. [PMID: 37992978 DOI: 10.1016/j.ijpharm.2023.123599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 11/24/2023]
Abstract
Gemcitabine (GEM) is an important chemotherapeutic agent used alone or in combination with other anticancer agents for the treatment of various solid tumors. In this study, the potential of a dietary supplement, α-tocopherol succinate (TOS) was investigated in combination with GEM by utilizing human serum albumin-based nanoparticles (HSA NPs). The developed nanoparticles were characterized using DLS, SEM and FTIR and evaluated in a panel of cell lines to inspect cytotoxic efficacy. The ratio metric selected combination of the NPs was further investigated in human pancreatic cancer cell line (MIA PaCa-2 cells) to assess the cellular death mechanism via a myriad of biochemical and bio-analytical assays including nuclear morphometric analysis by DAPI staining, ROS generation, MMP loss, intracellular calcium release, in vitro clonogenic assay, cell migration assay, cell cycle analysis, immunocytochemical staining followed by western blotting, Annexin V-FITC and cellular uptake studies. The desolvation-crosslinking method was used to prepare the NPs. The average size of TOS-HSA NPs and GEM-HSA NPs was found to be 189.47 ± 5 nm and 143.42 ± 7.4 nm, respectively. In combination, the developed nanoparticles exhibited synergism by enhancing cytotoxicity in a fixed molar ratio. The selected combination also significantly triggered ROS generation and mitochondrial destabilization, alleviated cell migration potential and clonogenic cell survival in MIA PaCa-2 cells. Further, cell cycle analysis, Annexin-V FITC assay and caspase-3 activation, up regulation of Bax and down regulation of Bcl-2 protein confirmed the occurrence of apoptotic event coupled with the G0/G1 phase arrest. Nanocarriers based this combination also offered approximately 14-folds dose reduction of GEM. Overall, the combined administration of TOS-HSA NPs and GEM-HSA NPs showed synergistic cytotoxicity accompanied with dose reduction of the gemcitabine. These encouraging findings could have implication in designing micronutrient based-combination therapy with gemcitabine and demands further investigation.
Collapse
Affiliation(s)
- Chittaranjan Behera
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Kamalpreet Kaur Sandha
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Nagma Banjare
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Monu Kumar Shukla
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Syed Mudassir Ali
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Manisha Singh
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
| | - Prem N Gupta
- PK-PD Tox & Formulation Section, Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| |
Collapse
|
4
|
Yin X, Zhao M, Zhou Y, Yang H, Liao Y, Wang F. Optimized methyl donor and reduced precursor degradation pathway for seleno-methylselenocysteine production in Bacillus subtilis. Microb Cell Fact 2023; 22:215. [PMID: 37853389 PMCID: PMC10585787 DOI: 10.1186/s12934-023-02203-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 09/08/2023] [Indexed: 10/20/2023] Open
Abstract
BACKGROUND Seleno-methylselenocysteine (SeMCys) is an effective component of selenium supplementation with anti-carcinogenic potential that can ameliorate neuropathology and cognitive deficits. In a previous study, a SeMCys producing strain of Bacillus subtilis GBACB was generated by releasing feedback inhibition by overexpression of cysteine-insensitive serine O-acetyltransferase, enhancing the synthesis of S-adenosylmethionine as methyl donor by overexpression of S-adenosylmethionine synthetase, and expressing heterologous selenocysteine methyltransferase. In this study, we aimed to improve GBACB SeMCys production by synthesizing methylmethionine as a donor to methylate selenocysteine and by inhibiting the precursor degradation pathway. RESULTS First, the performance of three methionine S-methyltransferases that provide methylmethionine as a methyl donor for SeMCys production was determined. Integration of the NmMmt gene into GBACB improved SeMCys production from 20.7 to 687.4 μg/L. Next, the major routes for the degradation of selenocysteine, which is the precursor of SeMCys, were revealed by comparing selenocysteine hyper-accumulating and non-producing strains at the transcriptional level. The iscSB knockout strain doubled SeMCys production. Moreover, deleting sdaA, which is responsible for the degradation of serine as a precursor of selenocysteine, enhanced SeMCys production to 4120.3 μg/L. Finally, the culture conditions in the flasks were optimized. The strain was tolerant to higher selenite content in the liquid medium and the titer of SeMCys reached 7.5 mg/L. CONCLUSIONS The significance of methylmethionine as a methyl donor for SeMCys production in B. subtilis is reported, and enhanced precursor supply facilitates SeMCys synthesis. The results represent the highest SeMCys production to date and provide insight into Se metabolism.
Collapse
Affiliation(s)
- Xian Yin
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
- China Food Flavor and Nutrition Health Innovation Center, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
| | - Meiyi Zhao
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
| | - Yu Zhou
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
| | - Hulin Yang
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China
| | - Yonghong Liao
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
- China Food Flavor and Nutrition Health Innovation Center, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
| | - Fenghuan Wang
- Key Laboratory of Geriatric Nutrition and Health (Ministry of Education), Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
- China Food Flavor and Nutrition Health Innovation Center, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
- School of Light Industry, Beijing Technology and Business University, Fucheng RD 11, Beijing, 100048, China.
| |
Collapse
|
5
|
Sodano F, Rolando B, Lazzarato L, Costamagna C, Failla M, Riganti C, Chegaev K. Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells. Int J Mol Sci 2023; 24:11258. [PMID: 37511019 PMCID: PMC10379931 DOI: 10.3390/ijms241411258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 06/27/2023] [Accepted: 07/06/2023] [Indexed: 07/30/2023] Open
Abstract
The application of gaseous signaling molecules like NO, H2S or CO to overcome the multidrug resistance in cancer treatment has proven to be a viable therapeutic strategy. The development of CO-releasing molecules (CORMs) in a controlled manner and in targeted tissues remains a challenge in medicinal chemistry. In this paper, we describe the design, synthesis and chemical and enzymatic stability of a novel non-metal CORM (1) able to release intracellularly CO and, simultaneously, facilitate fluorescent degradation of products under the action of esterase. The toxicity of 1 against different human cancer cell lines and their drug-resistant counterparts, as well as the putative mechanism of toxicity were investigated. The drug-resistant cancer cell lines efficiently absorbed 1 and 1 was able to restore their sensitivity vs. chemotherapeutic drugs by causing a CO-dependent mitochondrial oxidative stress that culminated in mitochondrial-dependent apoptosis. These results demonstrate the importance of CORMs in cases where conventional chemotherapy fails and thus open the horizons towards new combinatorial strategies to overcome multidrug resistance.
Collapse
Affiliation(s)
- Federica Sodano
- Department of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy
| | - Barbara Rolando
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy
| | - Loretta Lazzarato
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy
| | | | - Mariacristina Failla
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, 10125 Torino, Italy
| | - Konstantin Chegaev
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy
| |
Collapse
|
6
|
Singh V, Rana NK, Kashif M, Manna PP, Basu Baul TS, Koch B. Aqua-(2-formylbenzoato)triphenyltin(IV) induces cell cycle arrest and apoptosis in hypoxic triple negative breast cancer cells. Toxicol In Vitro 2023; 86:105484. [DOI: 10.1016/j.tiv.2022.105484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 09/21/2022] [Accepted: 10/11/2022] [Indexed: 11/07/2022]
|